DK0460076T3 - Genetisk manipulerede immunoglobuliner - Google Patents

Genetisk manipulerede immunoglobuliner

Info

Publication number
DK0460076T3
DK0460076T3 DK90904172.5T DK90904172T DK0460076T3 DK 0460076 T3 DK0460076 T3 DK 0460076T3 DK 90904172 T DK90904172 T DK 90904172T DK 0460076 T3 DK0460076 T3 DK 0460076T3
Authority
DK
Denmark
Prior art keywords
genetically engineered
engineered immunoglobulins
immunoglobulins
preparing
found
Prior art date
Application number
DK90904172.5T
Other languages
Danish (da)
English (en)
Inventor
Maurizio Zanetti
Maurizio Sollazzo
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23227670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0460076(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK0460076T3 publication Critical patent/DK0460076T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK90904172.5T 1989-02-24 1990-02-23 Genetisk manipulerede immunoglobuliner DK0460076T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31614489A 1989-02-24 1989-02-24

Publications (1)

Publication Number Publication Date
DK0460076T3 true DK0460076T3 (da) 1996-03-25

Family

ID=23227670

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90904172.5T DK0460076T3 (da) 1989-02-24 1990-02-23 Genetisk manipulerede immunoglobuliner

Country Status (9)

Country Link
US (3) US5508386A (fr)
EP (1) EP0460076B1 (fr)
JP (2) JP3355351B2 (fr)
AT (1) ATE130765T1 (fr)
CA (1) CA2047244C (fr)
DE (2) DE69023900D1 (fr)
DK (1) DK0460076T3 (fr)
ES (1) ES2082850T3 (fr)
WO (1) WO1990009804A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3355351B2 (ja) * 1989-02-24 2002-12-09 ユーロジェン・ホールディング・ソシエテ・アノニム 遺伝的に工作されたイムノグロブリン
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
ES2193240T3 (es) * 1996-05-15 2003-11-01 Altarex Inc Metodo y composicion para reconformar antigenos multi-epitopicos para iniciar una respuesta inmune.
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
US7361346B1 (en) * 1996-05-15 2008-04-22 Altarex Corp. Therapeutic compositions that produce an immune response
US20020081298A1 (en) * 1997-01-07 2002-06-27 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6737057B1 (en) * 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
JP2002507544A (ja) * 1997-11-14 2002-03-12 ユーロ−セルティーク，エス．エイ． 抗イディオタイプ応答を引き出す能力が増強された改変型の抗体
EP1042459A4 (fr) * 1997-12-24 2003-07-23 Diatech Pty Ltd Molecules bifonctionnelles
US7279462B1 (en) 1998-04-27 2007-10-09 Nevagen Llc Somatic transgene immunization and related methods
AU753753B2 (en) * 1998-11-13 2002-10-24 Euro-Celtique S.A. Contraceptive antibody vaccines
CA2362928A1 (fr) * 1999-02-25 2000-08-31 Tai-June Yoo Vaccin contre l'allergie aux acariens detriticoles contenant un adn plasmidique nu
CA2369616C (fr) * 1999-04-27 2009-09-15 Eurogen Holding, S.A. Immunisation transgenique somatique et procedes apparentes
AU1084901A (en) 1999-10-14 2001-04-23 Martha S. Hayden-Ledbetter Dna vaccines encoding antigen linked to a domain that binds cd40
AU2001241533A1 (en) * 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
KR100863632B1 (ko) 2000-03-31 2008-10-15 퍼듀 리서치 파운데이션 리간드-면역원 접합체를 사용한 치료 방법
WO2003002908A1 (fr) * 2000-06-26 2003-01-09 Reveo, Inc. Eclairage par l'arriere pour afficheur a cristaux liquides, a recyclage de flux lumineux tres efficace
GB0102145D0 (en) * 2001-01-26 2001-03-14 Scancell Ltd Substances
AU2002307062A1 (en) * 2001-04-02 2002-10-15 Purdue Pharma L.P. Thrombopoietin (tpo) synthebody for stimulation of platelet production
EP1497654A4 (fr) 2001-08-13 2006-06-07 Chen Swey Shen Alex Vaccins d'immunoglobuline e et leurs procedes d'utilisation
EP1434603B1 (fr) * 2001-09-28 2009-12-16 Purdue Research Foundation Methode de traitement utilisant des conjugues ligand-immunogene
US20070037769A1 (en) * 2003-03-14 2007-02-15 Multicell Immunotherapeutics, Inc. Compositions and methods to treat and control tumors by loading antigen presenting cells
JP2005526778A (ja) * 2002-03-15 2005-09-08 アストラル，インコーポレイテッド 免疫調節性非コードｒｎａモチーフを用いて抗体及び主要組織適合性クラスｉ拘束性又はクラスｉｉ拘束性ｔ細胞の応答を開始或いは増強させるための組成物及び方法
EP2258712A3 (fr) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions et procédés permettant d'initier ou d'ameliorer les réponses des cellules T limitées par le complexe majeur d 'histocompatibilité de classe I ou II et un anticorps au moyen de motifs d'ARN non codants immunomodulateurs
US8603471B2 (en) 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions for preventing the onset of type 1 diabetes
US8603472B2 (en) 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
US8609091B2 (en) 2002-04-09 2013-12-17 The Curators Of The University Of Missouri Method for endocytic presentation of an immunosuppressive for the treatment of type 1 diabetes
US7744876B2 (en) 2002-04-09 2010-06-29 The Curators Of The University Of Missouri Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes
US7939641B2 (en) 2002-04-09 2011-05-10 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
CA2481796A1 (fr) * 2002-04-11 2003-10-23 Altarex Medical Corporation Agents de liaison et leur utilisation dans le ciblage de cellules tumorales
NZ536609A (en) * 2002-04-19 2007-11-30 Endocyte Inc Use of an TH1-biasing adjuvant to enhance the immune response to the immunogen in immunotherapy
JP2006522806A (ja) * 2003-03-26 2006-10-05 マルチセル・イミュノセラピューティクス，インコーポレイテッド 細胞死及び／又はアポトーシスを誘導するための、選択されたｒｎａモチーフ
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
WO2006076683A2 (fr) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolement et detection de prions pathogenes
WO2006076687A2 (fr) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Dosages elisa utilisant des reactifs peptides specifiques du prion
US20070111237A1 (en) * 2005-09-14 2007-05-17 Maurizio Zanetti Process for identifying antigenized antibodies using ribosome cell free expression system
US8168164B2 (en) * 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
EP1887084A1 (fr) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmides avec l'action immunologique
US8865179B2 (en) * 2008-01-26 2014-10-21 Swey-Shen Alexchen Aptameric IgE peptides in a protein scaffold as an allergy vaccine
US20110189692A1 (en) * 2008-04-30 2011-08-04 Novartis Ag Assay for pathogenic conformers
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0110791B1 (fr) * 1982-11-30 1990-04-25 Institut Pasteur Peptides comportant un site immunogène du poliovirus et ADNs contenant des séquences nucléotidiques codant pour ces peptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4631191A (en) * 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
JP3355351B2 (ja) * 1989-02-24 2002-12-09 ユーロジェン・ホールディング・ソシエテ・アノニム 遺伝的に工作されたイムノグロブリン
JPH06506947A (ja) * 1991-04-18 1994-08-04 マウント　シナイ　スクール　オブ　メディスン　オブ　ザ　シティー　ユニバーシティー　オブ　ニューヨーク 抗ウィルスハイブリッド抗体

Also Published As

Publication number Publication date
US5508386A (en) 1996-04-16
US5583202A (en) 1996-12-10
CA2047244A1 (fr) 1990-08-25
JPH04503605A (ja) 1992-07-02
DE69023900D1 (de) 1996-01-11
JP3355351B2 (ja) 2002-12-09
US5658762A (en) 1997-08-19
ES2082850T3 (es) 1996-04-01
EP0460076B1 (fr) 1995-11-29
DE69023900T4 (de) 1996-10-02
ATE130765T1 (de) 1995-12-15
DE69023900T2 (de) 1996-07-04
EP0460076A1 (fr) 1991-12-11
WO1990009804A1 (fr) 1990-09-07
EP0460076A4 (en) 1992-08-05
JP2001190295A (ja) 2001-07-17
CA2047244C (fr) 2002-09-17
JP3357890B2 (ja) 2002-12-16

Similar Documents

Publication Publication Date Title
DK0460076T3 (da) Genetisk manipulerede immunoglobuliner
DE3484664D1 (de) Rekombinante immunoglobulin-praeparate, verfahren zu ihrer herstellung, dna-sequenzen, expressionsvektoren und rekombinante wirkzellen hierfuer.
EP0699755A3 (fr) Procédé pour obtenir des immunoglobulines modifiées avec une immunogénicité réduite des domaines variables d'un anticorps murin, compositions les contenant
SE9201331D0 (sv) Protein l och hybridproteiner daerav
DE69535719D1 (de) Fas-antigenbindender ligand
ATE206435T1 (de) Toxoplasma gondii-antigene, ihre herstellung und ihre verwendung
MX24652A (es) Compuestos de adn recombinante, vectores para la expresion de formas zimogenas de proteina c humana, celulas huesped transformadas y metodo para la prduccion recombinante de formas zimogenas de la proteina c humana.
NZ296564A (en) Method of improving antigenicity of antigens or haptens, fusion with rsv peptides; vaccines, vectors, nucleotides
DK1119630T3 (da) Nukleinsyrekonstruktioner til genetisk immunisering
DE69029808D1 (de) Monoklonale antikörper
SG95574A1 (en) Immunoreactive antigens of hepatitia e virus
DE68907735D1 (de) Genfragmente, die die variable region eines anti-hiv-antikoerpers codieren, von diesen exprimierte chimaere anti-hiv-antikoerper und verfahren zu deren herstellung.
ATE233811T1 (de) Blutplaettchen-gpiiia p1a1 und -p1a2-epitope, ihre herstellung und verwendung
DK218886A (da) Tvaerreaktive og beskyttende epitoper af circumsporozoit-proteiner
NO883501L (no) Slekt-spesifikt listeria-antigen identifisert med monoklonale antistoffer.
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
DK0476059T3 (da) Fremgangsmåder til forøgelse af modificeringshastigheden for metastabile bindinger
DE69931282D1 (de) Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
MX24651A (es) Compuestos de adn recombinante, vectores de expresion de mutantes de glicosilacion de la proteina c humana, celulas huesped transformadas y metodo para la produccion recombinante de formas zimogenas de proteina c humana.
DE69927190D1 (de) Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
DE69923092D1 (de) Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
ATE92102T1 (de) Genfragmente, die die variable region eines anti- hiv-antikoerpers codieren, von diesen exprimierte chimaere anti-hiv-antikoerper und verfahren zu deren herstellung.